Ra Capital Management, L.P., operating through its affiliated vehicles RA Capital Healthcare Fund LP and RA Capital Nexus Fund II, L.P., alongside managing members Peter Kolchinsky and Rajeev Shah, has disclosed a reduction in its position within Werewolf Therapeutics, Inc. (NASDAQ:HOWL). The reported activity encompasses a series of common stock sales executed over a five-day period from June 12 to June 16, 2026. Collectively, these transactions resulted in a total sales value of approximately $173,757.
The divestment activity is detailed across multiple Form 4 filings, revealing specific share counts and pricing dynamics. On June 12, 2026, RA Capital Healthcare Fund, L.P. disposed of 159,119 shares. These shares were sold at a weighted average price of $0.40, with individual transaction prices fluctuating between $0.3814 and $0.4129. Concurrently, RA Capital Nexus Fund II, L.P. offloaded 11,322 shares on the same date, adhering to the identical weighted average price and price range.
Subsequent selling pressure emerged on June 15, 2026. RA Capital Healthcare Fund, L.P. sold 120,216 shares at a weighted average price of $0.39, with transaction prices ranging from $0.3757 to $0.3955. RA Capital Nexus Fund II, L.P. participated in this day's activity as well, selling 8,554 shares at the same average price and within the same price boundaries.
The final reported transactions in this series occurred on June 16, 2026. RA Capital Healthcare Fund, L.P. executed the sale of 139,686 shares at a weighted average price of $0.37, with prices ranging from $0.3584 to $0.3906. RA Capital Nexus Fund II, L.P. contributed an additional 9,939 shares to this day's volume, also transacting at the same weighted average price and range.
Market context surrounding these transactions highlights significant downward pressure on the underlying asset. Werewolf Therapeutics stock currently trades at $0.36, a level that sits perilously close to its 52-week low of $0.35. This current valuation reflects a steep 72% decline in share price over the past year, indicating substantial bearish momentum in the biotechnology sector.
All reporting persons are identified as ten percent owners of Werewolf Therapeutics, Inc. Despite this significant ownership stake, they disclaim beneficial ownership of the reported securities, limiting their claim to their respective pecuniary interest. Ra Capital Management, L.P. serves as the investment manager for both affiliated funds involved in these transactions.
Analysis from InvestingPro suggests that the stock may appear undervalued at these current price levels. Subscribers tracking undervalued opportunities may find additional insights regarding potential valuation gaps. The rapid decline in share price and the subsequent institutional divestment raise questions regarding future valuation models and market sentiment within the healthcare and biotechnology sectors.